Real-World Effectiveness of Ceftazidime–Avibactam for Multidrug-Resistant Gram-Negative Pneumonia, Time-Stratified Risk Factors for Short- and Long-Term Mortality, and Inpatient Costs: A Multicenter Retrospective Cohort Study

Multidrug-resistant Gram-negative pneumonia carries significant morbidity and mortality, often requiring resource-intensive care. Ceftazidime–avibactam is an essential therapeutic option for these resistant infections. This retrospective, multicenter study evaluated the real-world clinical response